MX2021001610A - Polipeptidos de fhbp meningococicos modificados. - Google Patents

Polipeptidos de fhbp meningococicos modificados.

Info

Publication number
MX2021001610A
MX2021001610A MX2021001610A MX2021001610A MX2021001610A MX 2021001610 A MX2021001610 A MX 2021001610A MX 2021001610 A MX2021001610 A MX 2021001610A MX 2021001610 A MX2021001610 A MX 2021001610A MX 2021001610 A MX2021001610 A MX 2021001610A
Authority
MX
Mexico
Prior art keywords
fhbp polypeptides
meningococcal fhbp
modified meningococcal
polypeptides
modified
Prior art date
Application number
MX2021001610A
Other languages
English (en)
Inventor
Maria Scarselli
Daniele Veggi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2021001610A publication Critical patent/MX2021001610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona polipéptidos de fHbp mutados y proteínas de fusión que comprenden dichos polipéptidos de fHbp mutados que son útiles como componentes de composiciones inmunogénicas para inmunizar contra la infección por Neisseria meningitidis.
MX2021001610A 2018-08-09 2019-08-09 Polipeptidos de fhbp meningococicos modificados. MX2021001610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18188321.6A EP3607967A1 (en) 2018-08-09 2018-08-09 Modified meningococcal fhbp polypeptides
PCT/EP2019/071410 WO2020030782A1 (en) 2018-08-09 2019-08-09 Modified meningococcal fhbp polypeptides

Publications (1)

Publication Number Publication Date
MX2021001610A true MX2021001610A (es) 2021-04-19

Family

ID=63371487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001610A MX2021001610A (es) 2018-08-09 2019-08-09 Polipeptidos de fhbp meningococicos modificados.

Country Status (14)

Country Link
US (2) US11708394B2 (es)
EP (2) EP3607967A1 (es)
JP (2) JP7271654B2 (es)
KR (1) KR20210041594A (es)
CN (1) CN112566657A (es)
AU (1) AU2019318120B2 (es)
BR (1) BR112021000988A2 (es)
CA (1) CA3108355A1 (es)
EA (1) EA202190184A1 (es)
IL (1) IL280189A (es)
MA (1) MA53271A (es)
MX (1) MX2021001610A (es)
SG (1) SG11202100482UA (es)
WO (1) WO2020030782A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212723A1 (en) * 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
CN114681601A (zh) * 2020-12-31 2022-07-01 基础治疗有限公司 脑膜炎奈瑟氏球菌疫苗及其应用
MX2023009728A (es) 2021-02-19 2023-08-30 Sanofi Pasteur Inc Vacuna recombinante meningococica b.
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202115077D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Assay
GB202208089D0 (en) * 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) * 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2024030931A1 (en) 2022-08-03 2024-02-08 Sanofi Pasteur Inc. Adjuvanted immunogenic composition against neisseria meningitidis b
CN117264031B (zh) * 2023-11-03 2024-01-30 烟台派诺生物技术有限公司 一种B群脑膜炎奈瑟菌fHBP重组蛋白及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
DK1248647T3 (da) 2000-01-17 2010-09-27 Novartis Vaccines & Diagnostic Ydre membranvesikel (OMV) vaccine omfattende N. meningitidis serogruppe B ydre membranproteiner
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
MXPA03000822A (es) 2000-07-27 2004-11-01 Childrens Hosp & Res Ct Oak Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis.
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
JP2006506467A (ja) 2002-08-02 2006-02-23 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン組成物
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
EP2208999B1 (en) 2005-09-05 2014-08-27 GlaxoSmithKline Biologicals SA Serum bactericidal assay for N. meningitidis specific antisera
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
BR112012010531A2 (pt) * 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
EP2552942B1 (en) 2010-03-30 2017-12-27 Children's Hospital & Research Center at Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
AU2012301812A1 (en) 2011-08-31 2014-03-06 Children's Hospital & Research Center Oakland Engineered sequences to facilitate expression of antigens in neisseria and methods of use
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
HUE052293T2 (hu) * 2014-02-28 2021-04-28 Glaxosmithkline Biologicals Sa Módosított fHbp meningococcus-polipeptidek
CN106795208A (zh) * 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
EP3169358A1 (en) 2014-07-17 2017-05-24 GlaxoSmithKline Biologicals S.A. Meningococcus vaccines
CA3212723A1 (en) * 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof

Also Published As

Publication number Publication date
US20240132550A1 (en) 2024-04-25
US20210277069A1 (en) 2021-09-09
CN112566657A (zh) 2021-03-26
EA202190184A1 (ru) 2021-05-14
KR20210041594A (ko) 2021-04-15
WO2020030782A1 (en) 2020-02-13
CA3108355A1 (en) 2020-02-13
AU2019318120B2 (en) 2024-03-14
SG11202100482UA (en) 2021-02-25
MA53271A (fr) 2021-11-17
JP2021533748A (ja) 2021-12-09
EP3607967A1 (en) 2020-02-12
JP7271654B2 (ja) 2023-05-11
IL280189A (en) 2021-03-01
BR112021000988A2 (pt) 2021-04-27
EP3833388A1 (en) 2021-06-16
JP2023061971A (ja) 2023-05-02
US11708394B2 (en) 2023-07-25
AU2019318120A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
MX2021001610A (es) Polipeptidos de fhbp meningococicos modificados.
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX2021001706A (es) Compuestos de anillo fusionado.
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2020003355A (es) Composiciones de neisseria meningitidis y metodos respectivos.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
MX2019002968A (es) Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal.
MX2023000204A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
SA519401227B1 (ar) لقاح النيسرية السحائية
WO2018161049A8 (en) Compositions and methods for inducing hiv-1 antibodies
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX2023005421A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2019006105A (es) Conjugados de vmen-antigeno y uso de los mismos.
PH12021550441A1 (en) Modified pedv spike protein
MX2020001820A (es) Metodos para reforzar las respuestas inmunitarias.
BR112022001199A2 (pt) Imunoterapia para poliomavírus
EA202191403A1 (ru) Композиция с высокой концентрацией белка
ZA202202180B (en) Engineered hcv e2 immunogens and related vaccine compositions
MX2021001554A (es) Metodo de preparacion de una formulacion farmaceutica de anticuerpos.
MX2009011851A (es) Plasmidos de dna que tienen expresion y estabilidad mejoradas.
WO2016091890A3 (en) Meningitidis vaccines comprising subtilinases
MX2022000525A (es) Vacunas contra la ehrlichia y composiciones inmunogenicas.
EA201990625A1 (ru) Вакцина против neisseria meningitidis